Cancer cachexia is regulated by selective targeting of skeletal muscle gene products

Journal of Clinical Investigation

Volumn 114, Issue 3, 2004, Pages 370-378

  Acharyya, Swarnali ^a,b   Ladner, Katherine J ^a   Nelsen, Lori L ^a   Damrauer, Jeffrey ^a   Reiser, Peter J ^b   Swoap, Steven ^c   Guttridge, Denis C ^a,b,d  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c WILLIAMS COLLEGE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; CYTOKINE; GENE PRODUCT; MUSCLE PROTEIN; MYOSIN; MYOSIN HEAVY CHAIN; RNA; TROPOMYOSIN; TROPONIN T;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACHEXIA; CANCER; CONTROLLED STUDY; DOWN REGULATION; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE;

ANIMALS; CACHEXIA; CELL LINE, TUMOR; CHO CELLS; COLONIC NEOPLASMS; CRICETINAE; CRICETULUS; CYSTEINE ENDOPEPTIDASES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; INTERFERON TYPE II; MICE; MICE, INBRED STRAINS; MICE, NUDE; MULTIENZYME COMPLEXES; MUSCLE, SKELETAL; MYOD PROTEIN; MYOSIN HEAVY CHAINS; PROTEASOME ENDOPEPTIDASE COMPLEX; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITINS;

EID: 4043154377     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200420174     Document Type: Article

References (63)

1. Tisdale, M.J. 1997. Biology of cachexia. J. Natl. Cancer Inst. 89:1763-1773.
2. Argiles, J.M., Moore-Carrasco, R., Fuster, G., Busquets, S., and Lopez-Soriano, F.J. 2003. Cancer cachexia: the molecular mechanisms. Int. J. Biochem. Cell Biol. 35:405-409.
3. Tisdale, MJ. 2002. Cachexia in cancer patients. Nat. Rev. Cancer. 2:862-871.
4. Body, J.J. 1999. The syndrome of anorexia-cachexia. Curr. Opin. Oncol. 11:255-260.
5. Evans, W.K., et al. 1985. Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res. 45:3347-3353.
6. van Eys, J. 1985. Nutrition and cancer: physiological interrelationships. Annu. Rev. Nutr. 5:435-461.
7. Tracey, K.J., and Cerami, A. 1993. Tumor necrosis factor, other cytokines and disease. Annu. Rev. Cell Biol. 9:317-343.
8. Gelin, J., et al. 1991. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res. 51:415-421.
9. Barton, B.E. 2001. IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation. Immunol Res. 23:41-58.
10. Matthys, P., et al. 1991, Severe cachexia in mice inoculated with interferon-gamma-producing tumor cells. Int. J. Cancer. 49:77-82.
11. Aderka, D., et al. 1985. Cachectin/tumour-necrosis-factor production by cancer patients. Lancet. 2:1190.
12. Balkwill, F., et al. 1987. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet. 2:1229-1232.
13. Nakashima, J., et al. 1998. Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin. Cancer Res. 4:1743-1748.
14. Karayiannakis, A.J., et al. 2001. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res. 21:1355-1358.
15. Aleman, M.R., et al. 2002. Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine. 19:21-26.
16. Argiles, J.M., et al. 2000. The divergent effects of tumour necrosis factor-alpha on skeletal muscle: implications in wasting. Eur. Cytokine Netw. 11:552-559.
17. Ruan, H., Hacohen, N., Golub, T.R., Van Parijs, L., and Lodish, H.F. 2002. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3. L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes. 51:1319-1336.
18. Oliff, A., et al. 1987. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell. 50:555-563.
19. Tracey, K.J., et al. 1988. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J. Exp. Med. 167:1211-1227.
20. Costelli, P., et al. 1993. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J. Clin. Invest. 92:2783-2789.
21. Llovera, M., et al. 1998. Role of TNF receptor 1 in protein turn over during cancer cachexia using gene knockout mice. Mol. Cell. Endocrinol. 142:183-189.
22. Layne, M.D., and Farmer, S.R. 1999. Tumor necrosis factor-alpha and basic fibroblast growth factor differentially inhibit the insulin-like growth factor-I induced expression of myogenin in C2C12 myoblasts. Exp. Cell Res. 249:177-187.
23. Langen, R.C., Schols, A.M., Kelders, M.C., Wouters, E.F., and Janssen-Heininger, Y.M. 2001. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J. 15:1169-1180.
24. Guttridge, D.C., Albanese, C., Reuther, J.Y., Pestell, R.G., and Baldwin, A.S., Jr. 1999. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19:5785-5799.
25. Guttridge, D.C., Mayo, M.W., Madrid, L.V., Wang, C.-Y., and Baldwin, A.S., Jr. 2000. NF-κB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 289:2363-2366.
26. Moldawer, L.L., Svaninger, G., Gelin, J., and Lundholm, K.G. 1987. Interleukin 1 and tumor necrosis factor do not regulate protein balance in skeletal muscle. Am. J. Physiol. 253:C766-C773.
27. Spiegelman, B.M., and Hotamisligil, G.S. 1993. Through thick and thin: wasting, obesity, and TNF alpha. Cell. 73:625-627.
28. Argiles, J.M., and Lopez-Soriano, F.J. 1999. The role of cytokines in cancer cachexia. Med. Res. Rev. 19:223-248.
29. Todorov, P., et al. 1996. Characterization of a cancer cachectic factor. Nature. 379:739-742.
30. Carbo, N., et al. 2000. Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br. J. Cancer. 83:526-531.
31. Emery, P.W., Lovell, L., and Rennie, M.J. 1984. Protein synthesis measured in vivo in muscle and liver of cachectic tumor-bearing mice. Cancer Res. 44:2779-2784.
32. Batacos, V.E., DeVivo, C., Hoyle, D.H., and Goldberg, A.L. 1995. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am. J. Physiol. 268:E996-E1006.
33. Lecker, S.H., Solomon, V., Mitch, W.E., and Goldberg, A.L. 1999. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J. Nutr. 129(Suppl. 1):227S-237S.
34. Mitch, W.E., and Goldberg, A.L. 1996. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N. Engl. J. Med. 335:1897-1905.
35. Stitt, T.N., et al. 2004. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibited FOXO transcription factors. Mol. Cell. 14:395-403.
36. Sandri, M., et al. 2004. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 117:399-412.
37. Clark, K.A., McElhinny, A.S., Beckerle, M.C., and Gregorio, C.C. 2002. Striated muscle cytoarchitecture: an intricate web of form and function. Annu. Rev. Cell Dev. Biol. 18:637-706.
38. Ladner, K.J., Caligiuri, M.A., and Guttridge, D.C. 2003. Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. J. Biol. Chem. 278:2294-2303.
39. Ouaaz, F., and Beg, A.A. 1999. A critical role for the RelA subunit of nuclear factor kB in regulation of multiple immune-response genes and in Fas-induced cell death. J. Exp. Med. 189:999-1004.
40. Swoap, S.J. 1998. In vivo analysis of the myosin heavy chain IIB promoter region. Am. J. Physiol. 274:C681-C687.
41. Wheeler, M.T., Snyder, E.G., Patterson, M.N., and Swoap, S.J. 1999. An E-box within the MHC IIB gene is bound by MyoD and is required for gene expression in fast muscle. Am. J. Physiol. 276:C1069-C1078.
42. Davis, R.L., Cheng, P.F., Lassar, A.B., and Weintraub, H. 1990. The MyoD DNA binding domain contains a recognition code for muscle-specific gene activation. Cell. 60:733-746.
43. Strassmann, G., Fong, M., Kenney, J.S., and Jacob, C.O. 1992. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 89:1681-1684.
44. Strassmann, G., Masui, Y., Chizzonite, R., and Fong, M. 1993. Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor. J. Immunol. 150:2341-2345.
45. Yasumoto, K., et al. 1995. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res. 55:921-927.
46. Strassmann, G., et al. 1993. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J. Clin. Invest. 92:2152-2159.
47. Mendell, J.R., and Engel, W.K. 1971. The fine structure of type II muscle fiber atrophy. Neurology. 21:358-365.
48. Diffee, G.M., Kalfas, K., Al-Majid, S., and McCarthy, D.O. 2002. Altered expression of skeletal muscle myosin isoforms in cancer cachexia. Am. J. Physiol. 283:C1376-C1382.
49. Goldberg, A.L. 2000. Probing the proteasome pathway way. Nat. Biotechnol. 18:538-543.
50. Temparis, S., et al. 1994. Increased ATP-ubiquitin-dependent proteolysis in skeletal muscles of tumor-bearing rats. Cancer Res. 54:5568-5573.
51. Medina, R., Wing, S.S., and Goldberg, A.L. 1995. Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy. Biochem. J. 307:631-637.
52. Lecker, S.H., et al. 2004. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18:39-51.
53. Todorov, P.T., Field, W.N., and Tisdale, M.J. 1999. Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361). Br. J. Cancer. 80:1734-1737.
54. Acakpo-Satchivi, L.J., et al. 1997. Growth and muscle defects in mice lacking adult myosin heavy chain genes. J. Cell Biol. 139:1219-1229.
55. Garcia-Martinez, C., Costelli, P., Lopez-Soriano, F.J., and Argiles, J.M. 1997. Is TNF really involved in cachexia? Cancer Invest. 15:47-54.
56. Li, Y.P., and Reid, M.B. 2000. NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am. J. Physiol. 279:R1165-R1170.
57. Li, Y.P., et al. 2003. TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. FASEB J. 17:1048-1057.
58. Fong, Y., et al. 1989. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am. J. Physiol. 256:R659-R665.
59. Kaplan, E.H., et al. 1990. Phase 11 study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J. Natl. Cancer Inst. 82:208-212.
60. Krigel, R.L., et al. 1988. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon. Cancer Res. 48:3875-3881.
61. Li, Y.P., Schwartz, R.J., Waddell, I.D., Holloway, B.R., and Reid, M.B. 1998. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J. 12:871-880.
62. Solomon, V., and Goldberg, A.L. 1996. Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J. Biol. Chem. 271:26690-26697.
63. Williams, A.B., et al. 1999. Sepsis stimulates release of myofilaments in skeletal muscle by a calcium-dependent mechanism. FASEB J. 13:1435-1443.